Dr Rebecca Shakir

Background

Dr Rebecca Shakir obtained her medical degree at Imperial College School of Medicine, London. She trained in Clinical Oncology in Oxford, and is nearing completion of a DPhil at Green Templeton College, Oxford. She is a Clinical Oncology SpR at Oxford University Hospitals NHS Foundation Trust. In her role as Sherrington Lecturer she has organisational responsibility for the clinical medical students at Magdalen college.

Research

Dr Shakir joined the Clinical Trials Service Unit at the Nuffield Department of Population Health, Oxford, to undertake a dedicated period of research within Professor Sarah Darby’s group, under the supervision of Dr David Cutter. Her research is focused on determining the benefits and risks of radiotherapy used after chemotherapy for Hodgkin lymphoma. Dr Shakir is funded by an NIHR Doctoral Research Fellowship.

Publications

• Jones DA, Candio P, Shakir R, Ntentas G, Ramroth J, Gray AM, … Cutter DJ. (2022). Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry. Blood Advances, 6(3), pp. 909-919. doi: 10.1182/bloodadvances.2021006254
• Ntentas G, Dedeckova K, Andrlik M, Aznar MC, Shakir R, Ramroth J, … Cutter DJ. (2021). Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection. International Journal of Radiation Oncology, Biology, Physics, doi: 10.1016/j.ijrobp.2021.10.151
• Dodwell D, Shakir R. (2021). Assessing New Drugs in Advanced Cancer: Beyond Randomised Evidence. Clinical Oncology, 33(4), pp. e201-e202. doi: 10.1016/j.clon.2020.11.003
• Shakir R, Mikhaeel NG. (2020). A ray of hope in a dire situation: Radiotherapy for progression after chimeric antigen receptor T-cell therapy. British Journal of Haematology, 190(1), pp. 18-19. doi: 10.1111/bjh.16562
• Shakir R, Adams R, Cooper R, Downing A, Geh I, Gilbert D, Jacobs C, Jones C, Lorimer C, Namelo W, Sebag-Montefiore D, Shaw P, Muirhead R. (2020). International Journal of Radiation Oncology, Biology, Physics, 106(2), pp. 329-339. doi: 10.1016/j.ijrobp.2019.10.016